Company intelligence / Profile preview

Modella AI

Boston, Massachusetts, United Statesmodella.ai ↗

Ownership: Private
Development stage: Preclinical

Overview

PathChat DX has received FDA Breakthrough Device Designation as one of the first generative AI tools specifically trained for human pathology. It aims to enhance diagnostic precision and accelerate time to diagnosis. The product remains under further testing and regulatory review; no clinical trial results are published yet.[3][5] Judith has been launched as an interactive research tool but clinical validation status is not specified.[6]

Therapeutic areas: OtherOncology
Modalities: Device (AI software as a medical device)Non-pharmacological therapy (AI-driven diagnostics and workflow tools)
Industry: Pathology

Partnerships

Exclusive license with Mahmood Lab at Mass General Brigham[4]

Beyond the preview

Go deeper on Modella AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Modella AI.

Explore the full profile